Tejara Capital’s Janux Therapeutics JANX Stock Holding History

Tejara Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-29,800	Closed	-$688K	–	65
2025 Q2	$688K	Buy	+29,800	New	+$785K	0.32%	57

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tejara Capital's JANX Position: Q3 2025 in Review

Tejara Capital sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 29,800 shares — an estimated $688K sold.

Tejara Capital first reported a position in JANX in Q2 2025 and held it in 1 quarter. The position peaked at $688K in Q2 2025. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

Tejara Capital reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
Tejara Capital sold 29,800 Janux Therapeutics shares in Q3 2025, an estimated $688K.
Tejara Capital first reported a position in Janux Therapeutics in Q2 2025 and held it in 1 quarter.
Tejara Capital's Janux Therapeutics position peaked at $688K in Q2 2025.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Tejara Capital's 13F filing for Q3 2025, filed 4 Nov 2025.